CoChat

ACE Inhibition Preserves Renal Function Better than bT-blockade in the Treatment of Essential Hypertension

Himmelmann, Anders, Hansson, Lennart, Hansson, Bengt-Gouran, Hedstrand, Hans, Skogstroum, Kay, Ouhrvik, John, Furaungen, Andreas · 1995 · Blood Pressure
Cited by 48

The DOI matches its Crossref record.

Abstract

Antihypertensive treatment can slow down the decline in glomerular filtration rate (GFR) with time. In patients with diabetic nephropathy, angiotensin converting enzyme (ACE) inhibition has been shown to be more effective in this regard than conventional antihypertensive therapy. Whether this applies to the much larger population of patients with essential hypertension is not yet known. In the present study, the effects of two different antihypertensive therapies on the loss of GFR with time, determined with Cr51-EDTA clearance after 6, 12 and 24 months of treatment, were assessed in a prospective, randomised, double-blind trial in 257 patients with essential hypertension. All had normal renal function and none had diabetes mellitus or glucosuria. Proteinuria (dipstick positive or trace) was detected in 7 patients initially. The two therapeutic modalities were the ACE inhibitor cilazapril and the bT-adrenoceptor blocking agent atenolol. Both therapies were equally effective in lowering sytolic blood pressure (e.g. from 168 mmHg to 152 mmHg with cilazapril and from 170 mmHg to 155 mmHg with atenolol after 6 months, p < 0.001 for both). However, atenolol was slightly but significantly more effective in lowering the diastolic blood pressure at 6, 12 and 24 months. The decline in GFR with time was significantly smaller with cilazapril than with atenolol. After 6 months the reduction in GFR was 1.0 vs. 4.0 ml/min × 1.73 m2, p = 0.008 (cilazapril vs. atenolol) and after 12 months the corresponding changes were 2.0 vs. 4.5 ml/min × 1.73 m2, p = 0.04 and after 24 months 3.0 vs. 4.0 ml/min × 1.73 m2, respectively (n.s.). In comparison with an age-matched normotensive population the cilazapril treated group did not differ as regards the decline in GFR with time, whereas the atenolol treated group showed a significantly greater fall. These results indicate that ACE inhibitor therapy in hypertensive patients prevents the decline in GFR with time better than a bT-blocker-based regimen, at least during the first year of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/08037059509077575

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 48

Metadata

Authors
Himmelmann, A., Hansson, L., Hansson, B.-G., Hedstrand, H., Skogstroum, K., Ouhrvik, J., & Furaungen, A.
Venue
Blood Pressure
Published
1995-01
Volume
4
Issue
2
Pages
85-90
ISSN
  • 0803-7051 (ISSN-L)
  • 1651-1999
OpenAlex
W2016864446
Cited by
48
References
0
FWCI
2.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ACE Inhibition Preserves Renal Function Better than bT-blockade in the Treatment of Essential Hypertension. https://app.cochat.ai/papers/10.3109/08037059509077575
The paper
Himmelmann, A., Hansson, L., Hansson, B.-G., Hedstrand, H., Skogstroum, K., Ouhrvik, J., & Furaungen, A. (1995). ACE Inhibition Preserves Renal Function Better than bT-blockade in the Treatment of Essential Hypertension. Blood Pressure. https://doi.org/10.3109/08037059509077575

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.